In this article, we review the advances in CD30- and PD-1-targeted therapies in cHL, with a focus on major completed or ongoing studies on brentuximab vedotin, nivolumab, and pembrolizumab. Here, PDCD1 is linked to classic Hodgkin lymphoma.